as attached

Date: 02 September 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT FOR THE FY 2025-26 OF THE COMPANY Dear Sirs, Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report along with independent reasonable assurance statement of the Company for the Financial Year 2025-26 which also forms part of the Annual Report of the Company. Kindly take the above information on your records. Yours faithfully, Eris Lifesciences Limited Milind Talegaonkar Company Secretary and Compliance Officer ICSI Membership No.: A26493 Encl : A/a BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORTING SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1 Corporate Identity Number (CIN) of the Listed Entity L24232GJ2007PLC049867 2 Name of the listed entity Eris Lifesciences Limited 3 Year of incorporation 25-01-2007 Shivarth Ambit, Plot No 142/2, Ramdas Road, Off 4 Registered office address SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054 Shivarth Ambit, Plot No 142/2, Ramdas Road, Off 5 Corporate office address SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat-380054 6 E-mail address complianceofficer@erislifesciences.com 7 Telephone no. 07969661000 8 Website https://eris.co.in/ 9 Financial year for which reporting is being done 2025-26 Bombay Stock Exchange Limited (BSE) 10 Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited (NSE) 11 Paid-up capital Rs. 13,85,42,887/- Name and contact details (telephone, email address) of Mr. Milind Talegaonkar 12 the person who may be contacted in case of any queries Tel: 07969661000 on the BRSR report Email: complianceofficer@erislifesciences.com Disclosures in this Report are made on a standalone basis, 13 Reporting boundary unless otherwise specified under any particular disclosure. 14 Name of assurance provider B Kabra and Co 15 Type of assurance obtained Reasonable Assurance for BRSR Core KPIs II. Products/services Details of business activities (accounting for 90% of the turnover) Description of Main Activity Description of Business Activity % of Turnover of the entity 16 No. Manufacturing and Marketing of 01. Pharmaceutical 100% Pharmaceutical Products Products/Services sold by the entity (accounting for 90% of the entity’s Turnover) 17 Sr. No. Product/Service NIC Code % of totalTurnover contributed 01. Pharmaceutical Products 2100 100 III. Operations 18 Number of locations where plants and/or operations/offices of the entity are situated Location Number of plants Number of offices Total National 1 5 6 International 0 0 0 Note: The 6 locations mentioned in the table above covers Company’s manufacturing facility located in Guwahati, three office locations Ahmedabad (HO), Mumbai and Lucknow, and two Central Warehouse situated at Zirakpur and Guwahati. 19 Markets served by the entity A Number of locations Locations Number National (No. of States) 28 International (No. of Countries) 0 B What is the contribution of exports as a percentage of the total turnover of the entity: The standalone operations of Eris Lifesciences are limited to the domestic branded formulations segment, with no export-related activities during the reporting period. C A brief on types of customers The Company operates across chronic, sub-chronic, and acute therapeutic segments, including cardio-metabolic, VMN, dermatology, CNS, and women’s health, among others. Distribution is primarily facilitated through wholesale distributors, stockists, retail pharmacies, and e-commerce channels. IV. Employees 20 Details as of the end of the Financial Year A. Employees and workers (including differently abled) Male Female Other Total S. No. Particulars % (C % (D / (A) No. (B) % (B / A) No. (C) No. (D) /A) A) EMPLOYEES 1 Permanent (D) 2704 2612 96.60% 92 3.40% 0 0% 2 Other than Permanent (E)* 308 283 91.88% 25 8.12% 0 0% 3 Total employees (D + E) 3012 2895 96.12% 117 3.88% 0 0% WORKERS 1 Permanent (F) 54 53 98.15% 1 1.85% 0 0% 2 Other than Permanent (G) 10 10 100.00% 0 0.00% 0 0% 3 Total Workers (F + G) 64 63 98.44% 1 1.56% 0 0% * All employees and workers who are on probation have been considered under the ‘Other than Permanent’ category for employees and workers throughout this BRSR disclosure. Differently abled Employees and workers: Nil. During the reporting period, the Company did not have representation of differently abled employees in its workforce. However, the Company continues to strengthen its commitment towards building an inclusive and equitable workplace by exploring opportunities to enhance the participation of differently abled individuals across various functions and operations. 21 Participation/Inclusion/Representation of women No. and percentage of Females Total (A) No. (B) % (B / A) Board of Directors 8 1 12.50% Key Management Personnel 2 0 0.00% 22 Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent 27% 33% 28% 34% 57% 35% 35% 21% 35% Employees Permanent 25% 0% 24% 20% 0% 19% 38% 0% 38% Workers V. Holding, Subsidiary, and Associate Companies (including joint ventures) 23 (a) Names of holding / subsidiary / associate companies / joint ventures. Does the entity indicated % of at column A, participate Name of the holding / subsidiary / Indicate whether holding/ shares Sr. in the Business associate companies / joint ventures subsidiary/ associate/ held by No. Responsibility initiatives (A) joint venture listed of the listed entity? (Yes/ entity 1 Aprica Healthcare Limited Step Down Wholly Owned Subsidiary 100% Yes 2 Eris M. J. Biopharm Private Limited Subsidiary 70% Yes 3 Eris Therapeutics Limited Wholly Owned Subsidiary 100% Yes 4 Eris Oaknet Healthcare Private Limited Step Down Wholly Owned Subsidiary 100% Yes 5 Eris Healthcare Private Limited Wholly Owned Subsidiary 100% Yes 6 Eris Pharmaceuticals Limited Wholly Owned Subsidiary 100% Yes 7 Swiss Parenterals Limited Wholly Owned Subsidiary 100% Yes Eris BioNxt Private Limited 8 (Previously known as Chemman Wholly Owned Subsidiary 100% Yes Labs Private Limited) 9 Levim Lifetech Private Limited Step Down Associate Company 30% No VI. CSR Details 24 (i) Whether CSR is applicable as per section 135 of the Companies Act, 2013: (Yes/No): Yes (ii) Turnover (Rs. in Crores): 17,79.77 (iii) Net worth (Rs. in Crores): 3,195.46 VII. Transparency and Disclosures Compliances Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct Stakeholder group from Grievance FY 2025-26 FY 2024-25 whom complaint is Redressal Number of Number of Remarks Number of Number of Remarks received Mechanism complaints complaints complaints complaints in Place filed during pending filed during pending (Yes/No) (If the year resolution the year resolution 25 Yes, then at close of at the close provide the year of the year web-link for grievance redress policy) Communities Yes* 0 0 Nil 0 0 Nil Investors (other than Yes* 0 0 Nil 0 0 Nil shareholders) Shareholders Yes* 0 0 Nil 6 0 Nil Employees and Yes* 1 0 Nil 0 0 Nil workers Customers Yes* 0 0 Nil 0 0 Nil Value Chain partners Yes* 0 0 Nil 0 0 Nil Others (please specify) Yes* 0 0 Nil 0 0 Nil *At Eris Lifesciences, stakeholder trust and transparent communication remain an integral part of the way the Company conducts its business. The policies that guide the Company’s engagement with stakeholders, along with the related grievance redressal mechanisms, are available on the Company’s website at https://www.eris.co.in/investor-relations/corporate-governance in the grievance redressal [Showing first 8,000 characters — download PDF for full document]